1 Development and validation of treatment-decision algorithms for children evaluated for 2 pulmonary tuberculosis: an individual participant data meta-analysis

3 Kenneth S. Gunasekera, Olivier Marcy, Johanna Muñoz, Elisa Lopez-Varela, Moorine P. 4 Sekadde, Molly F. Franke, Maryline Bonnet, Shakil Ahmed, Farhana Amanullah, Aliya Anwar, 5 Orvalho Augusto, Rafaela Baroni Aurilio, Sayera Banu, Iraj Batool, Annemieke Brands, Kevin P. 6 Cain, Lucía Carratalá-Castro, Maxine Caws, Eleanor S. Click, Lisa M. Cranmer, Alberto L. 7 García-Basteiro, Anneke C. Hesseling, Julie Huynh, Senjuti Kabir, Leonid Lecca, Anna 8 Mandalakas, Farai Mavhunga, Aye Aye Myint, Kyaw Myo, Dorah Nampijja, Mark P. Nicol, 9 Patrick Orikiriza, Megan Palmer, Clemax Couto Sant'Anna, Sara Ahmed Siddigui, Jonathan P. Smith, Rinn Song, Nguyen Thuy Thuong Thuong, Vibol Ung, Marieke M. van der Zalm, Sabine 10 Verkuijl, Kerri Viney, Elisabetta G. Walters, Joshua L. Warren, Heather J. Zar, Ben J. Marais, 11 12 Stephen M. Graham, Thomas P. A. Debray, Ted Cohen, James A. Seddon 13

- 14 Author Affiliations
- 15 Listed at end of document

16 Keywords

17 Diagnostic algorithm, diagnostic system, tuberculosis, paediatric, clinical evidence, Diagnosis/*

18 clinical decision-making

19 Word count

- 20 Abstract: 300/300
- 21 Main article 3500/3500
- 22 References: 30
- 23 Figures: 3
- 24 Tables: 3

25 Corresponding author

- 26 Kenneth Gunasekera
- 27 350 George Street, 3F
- 28 New Haven, CT 06510
- 29 USA
- 30 e-mail: <u>kenneth.gunasekera@yale.edu</u>

31 ABSTRACT

32 Background: Many children with pulmonary tuberculosis remain undiagnosed and 33 untreated with related high morbidity and mortality. Diagnostic challenges in children include low 34 bacterial burden, challenges around specimen collection, and limited access to diagnostic 35 expertise. Algorithms that guide decisions to initiate tuberculosis treatment in resource-limited 36 settings could help to close the persistent childhood tuberculosis treatment gap. Recent 37 advances in childhood tuberculosis algorithm development have incorporated prediction 38 modelling, but studies conducted to date have been small and localised, with limited 39 generalizability.

40 Methods: We collated individual participant data including clinical, bacteriological, and 41 radiologic information from prospective diagnostic studies in high-tuberculosis incidence settings 42 enrolling children <10 years with presumptive pulmonary tuberculosis. Using this dataset, we 43 first retrospectively evaluated the performance of several existing treatment-decision algorithms 44 and then developed multivariable prediction models, investigating model generalisability using 45 internal-external cross-validation. A team of experts provided input to adapt the models into a 46 pragmatic treatment-decision algorithm with a pre-determined sensitivity threshold of 85% for 47 use in resource-limited, primary healthcare settings.

Findings: Of 4,718 children from 13 studies from 12 countries, 1,811 (38·4%) were
classified as having pulmonary tuberculosis; 541 (29·9%) bacteriologically confirmed and 1,270
(70·1%) unconfirmed. Existing treatment-decision algorithms had highly variable diagnostic
performance. Our prediction model had a combined sensitivity of 86% [95% confidence interval
(CI): 0·68-0·94] and specificity of 37% [95% CI: 0·15-0·66] against a composite reference
standard.

Interpretation: We adopted an evidence-based approach to develop pragmatic
algorithms to guide tuberculosis treatment decisions in children, irrespective of the resources
locally available. This approach will empower health workers in resource-limited, primary

- 57 healthcare settings to initiate tuberculosis treatment in children in order to improve access to
- 58 care and reduce tuberculosis-related mortality. These algorithms have been included in the
- 59 operational handbook accompanying the latest WHO guidelines on the management of
- 60 tuberculosis in children and adolescents.
- 61 **Funding:** World Health Organization, US National Institutes of Health

62 **RESEARCH IN CONTEXT**

63 Evidence before the study: Treatment-decision algorithms relate information gained in 64 the evaluation of children into an assessment of tuberculosis disease risk and empower 65 healthcare workers to make appropriate treatment decisions. Studies in primary healthcare 66 centres have demonstrated that use of treatment-decision algorithms can improve childhood 67 pulmonary tuberculosis case-detection and treatment initiation in settings with high-tuberculosis 68 incidence. To identify primary research studies on treatment-decision algorithm performance 69 evaluation and/or development for childhood pulmonary tuberculosis, we carried out a PubMed 70 search using the terms ('child*' OR 'paediatr*' OR 'pediatr*') AND ('tuberculosis' OR 'TB') AND 71 ('treatment-decision' OR 'algorithm' OR 'diagnos*') to identify primary research published in any 72 language prior to 29 June 2022.

73 We additionally consulted multiple experts in childhood pulmonary tuberculosis 74 diagnosis and management, and we referred to existing, published reviews of treatment-75 decision algorithms. With respect to treatment-decision algorithm performance, several studies 76 have retrospectively estimated the performance of treatment-decision algorithms in a single 77 geographic setting; a subset of these studies have also compared the performance of multiple 78 algorithms using data from a single geographic setting. With respect to treatment-decision 79 algorithm development, many existing algorithms have been developed without explicit analysis 80 of data from children with presumptive pulmonary tuberculosis, often developed from expert 81 consensus. Gunasekera et al. used model-based approaches to analyse diagnostic evaluations 82 data (e.g., clinical history, physical examination, chest radiograph, and results from rapid 83 molecular and culture testing for Mycobacterium tuberculosis) collected from children with presumptive pulmonary tuberculosis in a single geographic setting to inform the development of 84 85 a diagnostic algorithm while Marcy et al. and Fourie et al analysed data from multiple 86 geographic settings. However, these studies were relatively small with limited assessment of 87 generalisability.

88 Added value of this study: We collated individual participant data from 13 prospective 89 diagnostic studies from 12 countries including 4,718 children with presumptive pulmonary 90 tuberculosis from geographically diverse settings with a high incidence of tuberculosis in order 91 to 1) evaluate the performance of existing treatment-decision algorithms and 2) develop 92 multivariable logistic regression models to quantify the contribution of individual features to 93 discriminate tuberculosis from non-tuberculosis. A panel of child tuberculosis experts provided 94 input into performance targets and advised on how to incorporate scores derived from these 95 models into pragmatic treatment-decision algorithms to assist in the evaluation of children 96 presenting with presumptive pulmonary tuberculosis in primary healthcare centres.

97 **Implications of all the available evidence:** Our findings suggest that evidence-based, 98 pragmatic treatment-decision algorithms can be developed to make sensitive and clinically 99 appropriate decisions to treat a child with pulmonary tuberculosis. Although the specificity does 100 not reach optimal targets for childhood tuberculosis diagnosis, pragmatic treatment-decision 101 algorithms provide clinically relevant guidance that can empower health workers to start children 102 on tuberculosis treatment at the primary healthcare setting and will likely contribute to reducing 103 the case-detection gap in childhood tuberculosis. External, prospective evaluation of these 104 novel algorithms in diverse settings is required, including assessment of their accuracy, 105 feasibility, acceptability, impact, and cost-effectiveness. This work led to a new interim WHO 106 recommendation to support the use of treatment-decision algorithms in the evaluation of 107 children with presumptive tuberculosis in the 2022 updated consolidated guidelines on the 108 management of tuberculosis in children. Two algorithms developed from this work have been 109 included in the WHO operational handbook accompanying these guidelines.

110 INTRODUCTION

Tuberculosis is a leading cause of mortality among children worldwide,¹ accounting for 111 $\sim 2.5\%$ of the 6 million deaths in children <5 years each year.² Modelling suggests that more 112 113 than 96% of tuberculosis deaths in children and adolescents (<15 years) occurred in those not receiving tuberculosis treatment.³ The World Health Organization (WHO) estimates that fewer 114 115 than 50% of the 1.1 million children <15 years who develop tuberculosis are diagnosed; the 116 proportion is even lower among children <5 years, at about 27%.¹ Thus, efforts to improve 117 diagnosis, and thereby improve access to tuberculosis treatment, are an important opportunity 118 to reduce tuberculosis morbidity and deaths among children.

119 Diagnosing pulmonary tuberculosis among children is challenging as respiratory specimens tend to be paucibacillary, resulting in a low yield of bacteriologic confirmation.⁴ 120 121 Furthermore, collecting respiratory specimens from young children is invasive and requires 122 resources that are generally concentrated in higher-level healthcare centres. Thus, careful 123 symptom review, clinical examination, chest radiography, and history of Mycobacterium 124 tuberculosis (Mtb) exposure can inform treatment decisions in clinical care. However, paediatric 125 clinical expertise and resources to make a diagnosis are often limited at primary healthcare 126 centres. This limits treatment access and leads to either delays in treatment initiation or no treatment initiation which are associated with worse outcomes, including mortality.^{5,6} Facilitating 127 128 appropriate diagnostic assessment with rapid treatment initiation at healthcare settings where 129 children initially present could contribute to reductions in tuberculosis-related morbidity and 130 mortality.

131 Treatment-decision algorithms aim to standardise clinical assessment and decision-132 making. Algorithms relate information gained in the evaluation of children into an assessment of 133 tuberculosis disease risk and empower healthcare workers to make appropriate treatment 134 decisions. Adopting an algorithmic approach to treatment decision-making has been shown to 135 improve childhood tuberculosis case detection and treatment access at primary healthcare

settings.^{7,8} However, these algorithms were developed using consensus expert opinion rather
than analysis of data.

138 Recent approaches for algorithm generation have used data from cross-sectional 139 childhood tuberculosis diagnostic studies to quantify the contribution of clinical characteristics to the risk of tuberculosis disease.⁹⁻¹¹ Evidence-based approaches are objective and offer the 140 141 potential for validation; however, existing studies have been small and not generalisable. In this 142 study, we assembled individual participant data (IPD) from children investigated for presumptive 143 pulmonary tuberculosis. We then sought to first evaluate the performance of currently used 144 diagnostic algorithms and then develop evidence-based treatment-decision algorithms. This 145 work was conducted to inform the 2022 WHO guidelines for the management of tuberculosis in children and adolescents and the accompanying WHO operational handbook.^{12,13} 146

147 METHODS

148 Establishment of individual participant data

149 We identified potential sources of IPD through responses to a public WHO Global 150 Tuberculosis Programme Public Call for Data on the Management of Children with Tuberculosis 151 in July 2020 and through referral from paediatric tuberculosis experts. Studies were eligible for 152 inclusion if they 1) prospectively recruited consecutive participants <10 years (the definition of a 153 child in the 2022 WHO guideline) attending healthcare centres in high-tuberculosis incidence 154 countries for clinical evaluation of pulmonary tuberculosis and 2) provided a final research 155 classification of pulmonary tuberculosis for each child. Tuberculosis was classified using the 156 revised US National Institutes of Health (NIH) clinical case definitions of intrathoracic tuberculosis in children.¹⁴ Broadly, this defines a confirmed tuberculosis case as culture- or 157 158 Xpert MTB/RIF-confirmed Mtb from respiratory specimen(s); an unconfirmed tuberculosis case 159 as having symptoms, chest radiography findings, and/or immune tests of *Mtb* sensitivity 160 suggestive of tuberculosis (including follow-up to verify or rule out tuberculosis); and an unlikely

tuberculosis case as meeting criteria for neither confirmed nor unconfirmed tuberculosis. If the
 study did not use the NIH classification, we used the study-specific definition of unconfirmed
 tuberculosis and unlikely tuberculosis. Quality assessment was performed using a modified
 version of the Newcastle-Ottawa Scale for cohort studies.¹⁵

After identification of eligible studies, we requested IPD including details from the clinical history, physical examination, chest radiograph, and results from rapid molecular and culture testing for *Mtb* performed on respiratory specimens collected at study entry (<u>Supplementary</u> <u>Appendix A</u>). All data assembly and analysis were carried out using R software version 4.1.1. To account for the uncertainty associated with incomplete data, we used multilevel multiple imputation by chained equations (MICE) implemented in the *MICE* package to generate 100 imputed datasets (Supplementary Appendix B).¹⁶

172 Evaluation of existing treatment-decision algorithms

173 We identified existing treatment-decision algorithms and scores (henceforth referred to 174 as algorithms) to guide the evaluation of children with presumptive pulmonary tuberculosis 175 through consultation with members of the WHO Guideline Development Group (GDG) on the 176 management of tuberculosis in children and adolescents. We defined a composite reference 177 standard using the NIH definitions of confirmed and unconfirmed pulmonary tuberculosis to 178 evaluate the performance of these algorithms. We carried out a sensitivity analysis of 179 performance using a reference standard of confirmed pulmonary tuberculosis only (excluding 180 children with unconfirmed tuberculosis). We used the "reitsma" function from the R package 181 mada to pool study-level sensitivity and specificity estimates using a bivariate random effects meta-analysis (Supplementary Appendix C).^{17,18} 182

183 Prediction model development and validation

184 We developed a multivariable logistic regression model to predict pulmonary
185 tuberculosis using the composite reference standard in accordance with the Transparent

Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis standards
using the internal-external cross-validation framework.^{19,20} Predictors included clinical features
commonly considered in the evaluation of presumptive childhood pulmonary tuberculosis in
primary and secondary healthcare centres that were available in the data with <50%
missingness. We also built a model without chest radiograph data to inform predictions in
healthcare centres without access to radiology services.

192 To account for possible heterogeneity in the distribution of predictor and outcome 193 variables, we fit the prediction model separately in each study and subsequently pooled their 194 regression coefficients and respective standard errors. This approach was implemented in the "metapred" function of package metamisc.^{20,21} To account for missing data, we generated a 195 196 prediction model as described above from each of the 100 imputed datasets and then used 197 Rubin's rules to pool the regression coefficients and standard errors to generate a final, single prediction model and compute odds ratios with 95% confidence interval (95% CI).²² We 198 199 examined the c-statistic (also known as the area under the receiver operating characteristic 200 curve) to assess the model's ability to distinguish between children with tuberculosis and 201 unlikely tuberculosis, and we examined the observed:expected (O:E) ratio to assess whether 202 there were studies in which the model over- or under-predicted tuberculosis.

203 Algorithm development

204 To generate clinically and programmatically implementable algorithms, we scaled the 205 coefficient estimates for the parameters of the final prediction models (developed from all n 206 studies) to estimate scores for each parameter such that a combined score of >10 207 corresponded to classification of tuberculosis at fixed sensitivities of 90%, 85%, 80%, 75%, and 208 70% (Supplementary Appendix D). To estimate the sensitivity and specificity of the score in 209 classifying tuberculosis using the composite reference standard, study-level sensitivities and 210 specificities were pooled using the bivariate model of Reitsma et al. (implemented in the mada package) accounting for uncertainty introduced by imputation of missing data.^{17,18} As a 211

sensitivity analysis, we evaluated the performance of the score against a reference standard ofconfirmed pulmonary tuberculosis only.

We worked with staff from the WHO Global TB Programme to identify a group of experts in childhood tuberculosis (henceforth referred to as the expert group; <u>Supplementary Appendix</u> <u>E</u>) to advise on the development of two treatment-decision algorithms from these scores. Specifically, we sought advice on how to use this score within an algorithm intended to be used at primary healthcare centres and on selection of a performance target for the development of the score to be included within the algorithm.

220 Ethics

221 This study was approved by the Stellenbosch University Health Research Ethics

222 Committee (Ref No. X21/02/003) and the Yale Institutional Review Board (Ref No.

223 2000028046). All collaborating investigators confirmed institutional ethical approval for their224 original data collection.

225 **RESULTS**

226 Data assembly

227 Eighteen studies were identified as having potentially appropriate data, largely sourced from diagnostic evaluation studies. The study investigators for two studies were unable to 228 229 provide data in the necessary timeline and an additional three studies did not meet the inclusion 230 criteria. From the 13 included studies carried out in 12 countries, 4,718 IPD records from 231 children <10 years with presumptive pulmonary tuberculosis were available, of which, 541 232 (11.5%) were classified as having confirmed tuberculosis, 1.270 (26.9%) as having unconfirmed 233 tuberculosis and 2,818 (59.7%) unlikely tuberculosis (**Tables 1 and 2**; Supplementary 234 Appendices F and G). The data were predominantly collected at secondary or tertiary/referral 235 healthcare centres. Although each study was required to include children with presumptive 236 pulmonary tuberculosis, studies differed slightly with respect to inclusion criteria, variable

definitions, and reference classification of tuberculosis (<u>Supplementary Appendices H-K</u>). All
 contributing studies achieved quality assessment scores of 4/5 or 5/5. (<u>Supplementary</u>
 Appendix L).

240 Existing treatment-decision algorithm performance

241 We evaluated the performance of eight existing treatment-decision algorithms. One of 242 these algorithms was evaluated only on data from children living with HIV, and another 243 evaluated only on data from children without HIV. Because some algorithms considered 244 evidence that were not available in the IPD, we modified all algorithms slightly (Supplementary Appendix M). The sensitivities varied from 17% to 93% with specificities varying from 88% to 245 246 16% when evaluated against the composite reference standard (Figure 1; Supplementary 247 Appendix N). A sensitivity analysis evaluating performance to discriminate confirmed 248 tuberculosis from unlikely tuberculosis demonstrated marginally higher sensitivities and 249 comparable specificities to the performance in the entire dataset (Supplementary Appendix O). 250 Prediction model development and validation 251 Odds ratios and 95% CI of the predictors included in the model are displayed in Table 3.

The pooled c-statistic for the prediction model including chest x-ray features was 0.71 (95% CI:

253 0.66-0.76), with a summary O:E ratio of 0.90 (95% CI: 0.28-2.98). Additional internal-external

254 cross-validation c-statistic and O:E ratio estimates are included in <u>Supplementary Appendix P</u>.

255 Estimates for the model without chest x-ray features are included in <u>Supplementary Appendix</u>

256 <u>Q</u>.

257 Algorithm development

The scores derived from the model prediction coefficients that correspond to classification of all tuberculosis with respective sensitivities of 90%, 85%, 80%, 75%, and 70% can be found in <u>Supplementary Appendix R</u>. The study-level and summary performance of these scores in classifying tuberculosis can be found in <u>Supplementary Appendix S</u>.

262 To balance the consequences of untreated tuberculosis versus the consequences of 263 overtreatment, the expert group recommended a sensitivity threshold of 85% in classifying 264 tuberculosis using the composite reference standard, resulting in the development of a score 265 with a sensitivity of 0.86 (95% CI: 0.68-0.94) and a specificity of 0.37 (95% CI: 0.15-0.66) 266 (Figure 2). An analysis of the performance in classifying confirmed tuberculosis vs. unlikely 267 tuberculosis demonstrated a sensitivity of 0.88 (95% CI: 0.71-0.95) and specificity of 0.37 (95% 268 CI: 0.15-0.67) (Supplementary Appendix T). Under a sensitivity threshold of 85%, the model that 269 included only features from the baseline clinical evaluation (without chest x-ray findings) had a 270 sensitivity of 0.84 (95% CI: 0.66-0.93) and specificity of 0.30 (95% CI: 0.13-0.56) in classifying 271 tuberculosis (Supplementary Appendix U).

272 To adapt the scores into treatment-decision algorithms to be used at primary healthcare 273 centres, the expert group recommended the following triage steps prior to classification using 274 the score: 1) identifying children with clinical symptoms and signs requiring urgent referral to 275 higher levels of healthcare, and 2) stratifying children by risk of mortality and progression of 276 tuberculosis. Higher-risk children were defined by the expert group as those <2 years, severely 277 malnourished, and/or living with HIV. These children would be evaluated using the score at the 278 time of the initial evaluation. Children not meeting this definition would be treated for the most 279 likely non-tuberculosis condition and complete re-evaluation in 1-2 weeks: those with 280 persistent/worsening symptoms at follow-up would be evaluated using the score. The expert 281 group additionally recommended to pursue, wherever available, bacteriological testing on 282 respiratory and/or stool specimens with rapid molecular diagnostics for all children and urine 283 lateral flow assays for HIV-positive children to align with existing WHO recommendations²³.

The expert group recommendations resulted in the development of a treatment-decision algorithm (**Figure 3**), in which children <10 years with presumptive pulmonary tuberculosis are triaged by risk of tuberculosis-related morbidity and mortality prior to being evaluated for the presence of clinical and chest x-ray features to assign a score corresponding to tuberculosis

risk. A total score of >10 results in classification of tuberculosis with a sensitivity of 85%. Known
exposure to tuberculosis alone has a score >10, so this was placed above the other elements.
The same parameters were used to construct the treatment-decision algorithm from the model
without chest x-ray features (Supplementary Appendix V).

292 **DISCUSSION**

293 We assembled a large IPD dataset from nearly five thousand children from 294 geographically diverse, high-tuberculosis incidence settings to evaluate existing treatment-295 decision algorithms and develop new evidence-based treatment-decision algorithms to guide 296 evaluation of children with presumptive pulmonary tuberculosis. This algorithm-building 297 approach uses the best currently available data to provide practical guidance to healthcare 298 workers in primary healthcare settings to identify which clinical features, with or without chest x-299 ray assessment, indicate whether initiation of tuberculosis treatment is warranted. The newly 300 developed algorithms were incorporated into the WHO operational handbook to support implementation of the new consolidated guidelines.^{12,13} 301

302 Modelling diagnostic evaluations IPD provides a guantitative description of the strength 303 of evidence for childhood pulmonary tuberculosis treatment-initiation decisions. Of the clinical 304 features, only reported exposure to tuberculosis was independently sufficient to meet the 305 threshold for treatment initiation. This was true even in the model-based score without chest x-306 ray features, suggesting that none of the common clinical features could independently inform 307 highly sensitive/specific treatment decisions. While results from tuberculin skin testing were 308 used by studies to inform classification of tuberculosis and to improve imputation of missing 309 data, we did not include these in the algorithms given operational limitations in using tuberculin 310 skin testing at scale in high-burden settings. Of the chest X-ray features included in the 311 algorithm, the presence of intrathoracic lymphadenopathy and a miliary pattern, respectively, 312 were independently sufficient to start treatment. It is worth noting that inclusion of chest x-ray

features only increased the specificity of the score slightly as compared to the score developed from the model with clinical features only. Chest x-ray has additional utility in guiding childhood pulmonary tuberculosis treatment duration for severe vs. non-severe disease,²⁴ in monitoring TB treatment response (including associated complications and sequelae) and in the diagnosis of other non-tuberculosis intrathoracic pathology.

318 The decision to prioritise sensitivity in our algorithm development is critical to initiate 319 more children with tuberculosis on appropriate therapy; however, many children may be falsely 320 treated for tuberculosis given the resulting specificity. No test or algorithm meets the WHO-321 target sensitivity and specificity for a confirmatory diagnostic test for childhood pulmonary tuberculosis.²⁵ Thus, the expert group advised to develop an algorithm with a minimum 322 323 sensitivity target of 85% as an acceptable balance between sensitivity and the resulting 324 specificity. Tuberculosis treatment for drug-susceptible disease is relatively safe in children;²⁶ 325 especially considering the potentially severe consequences of a missed tuberculosis diagnosis. 326 However, falsely treating for tuberculosis carries risk of delayed diagnosis of other disease, drug 327 adverse events, and unnecessary burden on families and healthcare services. It should be 328 noted that while these performance estimates relate to the score component of the algorithm, 329 the overall sensitivity and specificity of the whole algorithm, including the triage steps, remains 330 unknown and should be evaluated prospectively. As low-risk children are made to wait prior to 331 being evaluated with the scored part of the algorithm, symptoms in some with diagnoses other 332 than tuberculosis will resolve, likely improving specificity.

We note that the model-based scoring component of the algorithm demonstrates considerable study-level heterogeneity in sensitivity and specificity. Although this IPD is the largest of its size compiled to date, there were not enough studies to quantitatively describe the features that drive the observed heterogeneity. Given that we used data made available to WHO following a public call rather than conducting a systematic review, it is possible that some diagnostic studies may have been excluded. The inclusion of more data from existing, ongoing,

339 and future studies, may allow meta-regression to describe study-level sources of heterogeneity. 340 Heterogeneity may have been driven in part by varied tuberculosis prevalence in the cohorts 341 included as well as heterogeneities in disease presentation. Given that the pre-existing 342 treatment-decision algorithms demonstrated similar heterogeneities in performance compared 343 to the evidence-based algorithm developed, we suggest that our approach is robust as it offers 344 the flexibility to further interrogate the sources of heterogeneity as additional data are available. 345 A distinct advantage of the modelling approach we used for algorithm development is the ability 346 to revise and calibrate the model to specific settings as additional data become available.

347 We considered it important to evaluate existing treatment-decision algorithms and 348 develop new algorithms using a composite standard rather than solely a microbiological 349 standard, given the high percentage of children treated for tuberculosis without bacteriological 350 confirmation, even in the best resourced settings, which reflects the paucibacillary nature of 351 disease in most young children. However, this reference standard remains imperfect, and misclassification may occur.²⁷ The underlying composition of the unconfirmed tuberculosis 352 353 group may represent a heterogeneous group in which some children have tuberculosis, and 354 some have other causes for their observed symptoms and signs. Additionally, it is possible that 355 inclusion of unconfirmed pulmonary tuberculosis biased the estimation of the prediction model 356 parameters, especially those used to classify the unconfirmed group. Although this is a limitation 357 of our study, the similar performance estimates of the score developed in the primary analysis 358 using both the composite and confirmed tuberculosis reference standards suggest that this may 359 not be a major issue.

Given that our algorithms are intended to guide decisions to treat children in primary healthcare centres, it is a limitation that IPD was derived from primarily tertiary and referral health centres. We are not aware of studies that provide this quality of diagnostic evaluations data from presumptive childhood tuberculosis in primary healthcare centres. However, in several studies, children presenting at primary healthcare settings were directly referred for

365 study evaluation, providing some degree of reassurance as to the generalisability of results. The 366 pre-test probability of tuberculosis (i.e., the prevalence) is likely substantially lower among 367 children attending primary healthcare centres and the clinical presentation may be different as 368 compared to tertiary and referral centres from which the data were obtained. These are important given that many children with tuberculosis first present to primary healthcare 369 centres.²⁸ We believe that the risk-stratification and delayed entry of lower risk children with 370 371 presumptive tuberculosis (who should tolerate the delay) is a practical attempt to safely raise 372 the pre-test probability when implementing the algorithm in primary health centres. Prospective 373 external validation of the entire algorithms will be critical to determining their accuracy, 374 acceptability and feasibility of use at different levels of the healthcare system.

375 There are inherent limitations to developing a prediction model developed on data from 376 multiple cohorts for a disease with an imperfect diagnostic gold standard. Study inclusion criteria 377 varied, which impacts the baseline tuberculosis prevalence and applicability of the score 378 prediction estimates. Additionally, prediction variable definitions varied among the included 379 studies-for example, history of weight loss was variably defined as caregiver reported history 380 of weight loss or objective weight loss and/or deviation from previous growth trajectory. This 381 heterogeneity is also true for the study-level reference classifications, especially for unconfirmed 382 tuberculosis. Some studies used a previous version of the NIH reference classification, which 383 included probable and possible tuberculosis categories that we reclassified as unconfirmed tuberculosis, despite limitations using this approach.²⁹ These may contribute to heterogeneities 384 385 in estimating the association between the predictors and the outcome of tuberculosis. Finally, 386 we note that using a prespecified prediction model, as we did, may lead to overfitting.³⁰ Despite 387 a reasonable summary O:E ratio for our model, the heterogeneity in study-level O:E ratio 388 demonstrated in our internal-external cross-validation suggests that overfitting may be an issue. 389 As more data become available, future investigation into the causes driving heterogeneity may 390 inform more nuanced use of this algorithm within specific contexts and populations.

391 Pragmatic treatment-decision algorithms can lead to better detection of tuberculosis in 392 children, with improved access to early treatment and reduced tuberculosis morbidity and 393 mortality. Although we developed these algorithms using a thorough modelling analysis of a 394 large high-quality IPD dataset, the disappointing specificity of the scoring component suggests that improved diagnostic tools will be necessary to meet sensitivity and specificity targets. As 395 396 these diagnostic tools are identified, their data may be incorporated into treatment-decision 397 algorithms to improve the specificity of the algorithms while maintaining high sensitivity. 398 Additionally, decision-analytic modelling of the relative "cost" of false positive versus false 399 negative classification of tuberculosis and prevalence of tuberculosis may provide insight to 400 select an appropriate sensitivity threshold in future algorithm development.

Treatment-decision algorithms are now conditionally recommended by the WHO in the evaluation of children with presumptive tuberculosis, which should lead to improved diagnostic capacity at and treatment initiation at primary healthcare centres where paediatric tuberculosis expertise may be lacking. This work represents a paradigm shift in pragmatic and evidencebased approaches using advanced analytic methods to develop algorithms that draw on the best globally available data. This approach can be further improved and interrogated as additional data and diagnostic tools become available.

409 **REFERENCES**

410 1. World Health Organization. Global tuberculosis report 2021. Geneva: World Health411 Organization; 2021.

Perin J, Mulick A, Yeung D, et al. Global, regional, and national causes of under-5
mortality in 2000-19: an updated systematic analysis with implications for the Sustainable
Development Goals. *Lancet Child Adolesc Health* 2022; 6(2): 106-15.

3. Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of
tuberculosis mortality in children: a mathematical modelling study. *Lancet Glob Health* 2017;
5(9): e898-e906.

418 4. Detjen AK, DiNardo AR, Leyden J, et al. Xpert MTB/RIF assay for the diagnosis of
419 pulmonary tuberculosis in children: a systematic review and meta-analysis. *Lancet Resp Med*420 2015; 3(6): 451-61.

5. Naidoo P, Theron G, Rangaka MX, et al. The South African tuberculosis care cascade: estimated losses and methodological challenges. *J Infect Dis* 2017; **216**(Suppl 7): S702-S13.

423 6. Wobudeya E, Jaganath D, Sekadde MP, Nsangi B, Haq H, Cattamanchi A. Outcomes of
424 empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015. *BMC Public Health*425 2019; **19**(1): 446.

426 7. Zawedde-Muyanja S, Nakanwagi A, Dongo JP, et al. Decentralisation of child
427 tuberculosis services increases case finding and uptake of preventive therapy in Uganda. *Int J*428 *Tuberc Lung Dis* 2018; **22**(11): 1314-21.

429 8. Van Brusselen D, Simons E, Luendo T, et al. Improving pediatric TB diagnosis in North
430 Kivu (DR Congo), focusing on a clinical algorithm including targeted Xpert MTB/RIF on gastric
431 aspirates. *Confl Health* 2020; **14**: 26.

432 9. Fourie PB, Becker PJ, Festenstein F, et al. Procedures for developing a simple scoring
433 method based on unsophisticated criteria for screening children for tuberculosis. *Int J Tuberc*434 *Lung Dis* 1998; **2**(2): 116-23.

435 10. Gunasekera KS, Walters E, van der Zalm MM, et al. Development of a treatment436 decision algorithm for human immunodeficiency virus–uninfected children evaluated for
437 pulmonary tuberculosis. *Clin Infect Dis* 2021.

438 11. Marcy O, Borand L, Ung V, et al. A treatment-decision score for HIV-infected children
439 with suspected tuberculosis. *Pediatrics* 2019; **144**(3): e20182065.

- 440 12. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 5:
 441 management of tuberculosis in children and adolescents. Geneva: World Health Organization;
 442 2022.
- 443 13. World Health Organization. WHO operational handbook on tuberculosis. Module 5:
 444 management of tuberculosis in children and adolescents. Geneva: World Health Organization;
 445 2022.
- 446 14. Graham SM, Cuevas LE, Jean-Philippe P, et al. Clinical case definitions for classification
 447 of intrathoracic tuberculosis in children: an update. *Clin Infect Dis* 2015; **61**: s179-87.
- 448 15. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing
 449 the quality of nonrandomised studies in meta-analyses
- 450 <u>https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</u>.

- 451 16. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained 452 equations in R. *J Stat Softw* 2011; **45**(3): 1-67.
- 453 17. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH.
 454 Bivariate analysis of sensitivity and specificity produces informative summary measures in
 455 diagnostic reviews. *J Clin Epidemiol* 2005; **58**(10): 982-90.
- 456 18. Doebler P. mada: Meta-analysis of diagnostic accuracy. 2020.
- 457 19. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a
 458 multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD
 459 statement. *Br Med J* 2015; **350**: g7594.
- 20. Debray TP, Damen JA, Riley RD, et al. A framework for meta-analysis of prediction
 model studies with binary and time-to-event outcomes. *Stat Methods Med Res* 2019; **28**(9):
 2768-86.
- 463 21. Debray T, de Jong V. metamisc: meta-analysis of diagnosis and prognosis research
 464 studies. R package version 0.2.4/r584. <u>https://R-Forge.R-project.org/projects/metamisc/</u>. 2021.
- 465 22. Heymans MW, Eekhout I. Applied missing data analysis with SPSS and (R)Studio; 2019.
- 466 23. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3:
 467 diagnosis rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health
 468 Organization; 2021.
- 469 24. Turkova A, Wills GH, Wobudeya E, et al. Shorter treatment for nonsevere tuberculosis in 470 African and Indian children. *N Engl J Med* 2022; **386**(10): 911-22.
- 471 25. World Health Organization. High-priority target product profiles for new tuberculosis
 472 diagnostics: report of a consensus meeting. Geneva, Switzerland; 2014.
- 473 26. Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in 474 children: review. *Trop Med Int Health* 2009; **14**(11): 1329-37.
- 475 27. Wong M, Coit JM, Mendoza M, et al. Incident tuberculosis diagnoses in children at high
 476 risk for disease. *Open Forum Infect Dis* 2021; **8**(3).
- 28. Zawedde-Muyanja S, Reuter A, Tovar MA, et al. Provision of decentralized TB care
 services: a detect-teat-prevent strategy for children and adolescents affected by TB. *Pathogens*2021; **10**(12): 1568.
- 480 29. Marcy O, Goyet S, Borand L, et al. Tuberculosis diagnosis in HIV-infected children:
 481 comparison of the 2012 and 2015 clinical case definitions for classification of intrathoracic
 482 tuberculosis disease. *J Pediatr Infect Dis* 2021.
- 483 30. Steyerberg E. Clinical prediction models: a practical approach to development,
 484 validation, and updating. New York, NY: Springer-Verlag New York; 2009.
- 485

486 AUTHOR CONTRIBUTIONS

- 487 Conceptualization: KSG, OM, JAS
- 488 Data curation: KSG, OM, EL-V, MFF, MB, SA, FA, AA, OA, RBA, SB, IB, KPC, LC, MC, ESC,
- 489 ALG-B, ACH, JH, SK, LL, AAM, KM, DN, MPN, PO, MP, CCS, SAS, JPS, RS, NTTT, VU,
- 490 MMvdZ, EGW, HJZ

- 491 Formal analysis: KSG, OM, JM, JLW, TPAD, TC, JAS
- 492 Funding acquisition: KSG, AB, SV, KV, TC, JAS
- 493 Investigation: KSG, OM, JM, EL-V, MPS, MFF, MB, SA, FA, AA, OA, RBA, SB, IB, AB, KPC,
- LC, MC, ESC, ALG-B, ACH, JH, SK, AM, FM, AAM, KM, DN, MPN, PO, MP, CCS, SAS, JPS,
- 495 RS, NTTT, VU, MMvdZ, SV, KV, EGW, JLW, HJZ, BJM, SMG, TPAD, TC, JAS
- 496 Methodology: KSG, OM, JM, AB, SV, KV, TPAD, TC, JAS
- 497 Software: JM, TPAD
- 498 Validation: KSG, JAS
- 499 Visualization: KSG
- 500 Writing original draft: KSG, TC, JAS
- 501 Writing review & editing: all authors

502 ROLE OF THE FUNDING SOURCE

503 This work was supported by the WHO Global Tuberculosis Programme (GTB) as well as 504 the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the

505 United States National Institutes of Health (NIH). It was used to inform WHO consolidated

506 guidelines on tuberculosis management of TB in children and adolescents and the

507 accompanying operational handbook, both published by WHO in March 2022. This research

508 was also supported in part by the President's Emergency Plan for AIDS Relief (PEPFAR)

509 through the Centers for Disease Control and Prevention (CDC).

510 Disclaimer

511 Staff from the WHO GTB as well as staff from the CDC are co-authors of this paper, 512 offered feedback on the methodology and investigation, reviewed the manuscript, and made the 513 decision to submit. The authors alone are responsible for the views expressed in this article and 514 they do not necessarily represent the views, decisions or policies of the NIH, the WHO, the 515 CDC, and PEPFAR. 516

517 **ACKNOWLEDGEMENTS**

518 KSG was supported by the NIH the Eunice Kennedy Shriver National Institute of Child 519 Health and Human Development [F30HD105440] as well as the Yale Medical Scientist Training 520 Program [T32GM007205]. SA, SB and SK received funding support from USAID through 521 Research for Decision Makers' Activity, and the paper was prepared through the Structured 522 Operational Research and Training Initiative (SORT IT), a global partnership led by the Special 523 Program for Research and Training in Tropical Diseases at the World Health Organization. LMC 524 was supported by the NIH/NIAID (K23 AI143479). RS was supported by the NIH through the 525 Eunice Kennedy Shriver National Institute of Child Health and Human Development 526 (K23HD072802). MMVDZ is supported by a career development grant from the EDCTP2 527 program supported by the European Union (TMA2019SFP-2836 TB lung-FACT2), the Fogarty 528 International Center of the National Institutes of Health (Award Number K43TW011028) and by 529 funding from the South African Medical Research Council. EW was supported by a scholarship 530 for doctoral studies from the Medical Research Council of South Africa under MRC Clinician 531 Researcher Programme, the Faculty of Medicine and Health Sciences at Stellenbosch 532 University (Early Career Grant and Temporary Research Assistantship grant), the Harry 533 Crossley Foundation and the South African National Research Foundation (Thuthuka 534 programme funding for doctoral students). HJZ and MPN received funding from the NIH 535 (R01HD058971) and the Regional Prospective Observational Research in Tuberculosis 536 Consortium, co-funded by MRC of South Africa and NIH. TC and JLW were supported by the 537 NIH through the Institute of Allergy and Infectious Disease [R01AI147854 and R01AI137093, 538 respectively]. JAS was supported by a Clinician Scientist Fellowship jointly funded by the UK 539 Medical Research Council (MRC) and the UK Department for International Development (DFID) 540 under the MRC/DFID Concordat agreement (MR/R007942/1).

541 We acknowledge the patients and their caregivers for their willingness to participate in 542 each individual study. We hope that their contribution will benefit other families affected by 543 tuberculosis. We additionally would like to thank the following individuals who contributed to 544 execution of this work: Albert Okumu, Andrea T. Cruz, Carlos M. Perez-Velez, Chad Heilig, 545 Colleen Wright, Elisha Okeyo, Ha Thi Minh Đang, Hendrik Simon Schaaf, James Orwa, Lazarus 546 Odeny, Lesley Workman, Maria R. Jaswal, Mariaem Andres, Mark Fajans, Moe Zaw, Parisa 547 Hariri, Patrice Ahenda, Prisca Rabuogi, Rose Abwunza, Rumana Nasrin, Sabrina Choudhury, 548 Scott Lee, Shaikh Shumail, Shoaib Ahmed, Susan Musau, Syed Mohammad Mazidur Rahman, 549 Walter Mchembere, Yi Kyaw, Leonardo Martinez, Vivian Cox, Bryan Vonasek, and Alexander 550 Kay. Finally, we would like to acknowledge the members of the WHO Guideline Development 551 Group who considered this evidence to inform the 2022 WHO consolidated guidelines on the 552 management of tuberculosis in children and adolescents.

553

554 **DATA AVAILABILITY**

555 Data is available upon written request to the authors.

TABLES

Table 1. Study-level descriptions of data included in the individual participant dataset. HIV – human immunodeficiency virus, SAM –

severely acutely malnourished, PTB – pulmonary tuberculosis, Refs – references, BD – Bangladesh, BR – Brazil, KE – Kenya, MM – Myanmar,
 Multi – Multi-country study (includes Burkina Faso, Cameroon, Vietnam, and Cambodia), MZ – Mozambique, PK – Pakistan, UG – Uganda, VN –

560 Vietnam, ZA – South Africa. *Note: Modified version of the Newcastle-Ottawa Scale for cohort studies.

| Study | Size | <2 years | <5 years | HIV | SAM | Confirmed PTB | Unconfirmed PTB | Unlikely PTB | NOS* |
|---------------------|-------|------------|------------|-----------|----------|------------------|--------------------|-----------------|------|
| | N | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Aurilio/2020/BR | 50 | 21 (42) | 31 (62) | 6 (12) | 0 (0) | 9 (18) | 11 (22) | 24 (48) | 5/5 |
| Giang/2015/VN | 113 | 86 (76) | 106 (94) | 0 (0) | 8 (7) | 20 (18) | 77 (68) | 16 (14) | 5/5 |
| Hamid/2019/PK | 445 | 41 (9) | 175 (39) | 0 (0) | 26 (6) | 0 (0) | 29 (7) | 416 (93) | 5/5 |
| Kabir/2020/BD | 402 | 219 (54) | 296 (74) | 0 (0) | 93 (23) | 63 (16) | 36 (9) | 303 (75) | 4/5 |
| LopezVarela/2015/MZ | 789 | 549 (70) | 789 (100) | 104 (13) | 68 (9) | 13 (2) | 128 (16) | 648 (82) | 4/5 |
| Marcy/2019/Multi | 338 | 78 (23) | 142 (42) | 338 (100) | 64 (19) | 41 (12) | 155 (46) | 142 (42) | 5/5 |
| Myo/2018/MM | 223 | 72 (32) | 150 (67) | 27 (12) | 46 (21) | 27 (12) | 84 (38) | 112 (50) | 5/5 |
| Orikiriza/2018/UG | 338 | 124 (37) | 222 (66) | 101 (30) | 41 (12) | 12 (4) | 145 (43) | 167 (49) | 5/5 |
| Orikiriza/2022/UG | 217 | 157 (72) | 196 (90) | 70 (32) | 108 (50) | 12 (6) | 58 (27) | 125 (58) | 4/5 |
| Song/2021/KE | 300 | 146 (49) | 300 (100) | 73 (24) | 8 (3) | 31 (10) | 65 (22) | 170 (57) | 4/5 |
| Valencia/2017/MZ | 142 | 59 (42) | 95 (67) | 70 (49) | 27 (19) | 5 (4) | 28 (20) | 109 (77) | 5/5 |
| Walters/2017/ZA | 595 | 389 (65) | 548 (92) | 70 (12) | 18 (3) | 119 (20) | 180 (30) | 283 (48) | 5/5 |
| Zar/2019/ZA | 766 | 362 (47) | 603 (79) | 137 (18) | 32 (4) | 189 (25) | 274 (36) | 303 (40) | 5/5 |
| Total IPD | 4 718 | 2 303 (49) | 3 653 (77) | 996 (21) | 539 (11) | 541 (11) | 1 270 (27) | 2 818 (60) | |

Table 2. Characteristics of individual participant dataset. All clinical, bacteriology, and imaging data
 collected from the initial evaluation. IPD – Individual participant data, IQR – interquartile range, BCG –
 bacille Calmette-Guerin, HIV – human immunodeficiency virus, Mtb – *Mycobacterium tuberculosis*, CXR –
 chest x-ray, TST – tuberculin skin test.

| | Variable | Value | Confirmed tuberculosis | Unconfirmed tuberculosis | Unlikely tuberculosis | |
|--|-------------------------|---------------------------------|---------------------------|-----------------------------|--------------------------|--|
| | | | (N=541) | (N=1 270) | (N=2 818) | |
| | | | n (%) OR median (IQR) | n (%) OR median (IQR) | n (%) OR median (IQR) | |
| | A # 0 | Months | 25.6 (12,58.7) | 24.1 (12,53.6) | 24.4 (13.4,54) | |
| | Age | Unknown | 0 (0) | 0 (0) | 0 (0) | |
| | | Male | 285 (53) | 715 (56) | 1512 (54) | |
| | Sex | Female | 256 (47) | 554 (44) | 1306 (46) | |
| | | Unknown | 0 (0) | 1 (0) | 0 (0) | |
| | | z-score | -1.7 (-2.9,-0.6) | -1.7 (-2.9,-0.6) | -1.8 (-3,-0.7) | |
| | Weight-for-age | Unknown | 7 (1) | 16 (1) | 119 (4) | |
| | | Evidence of BCG | | | | |
| | | vaccination | 462 (85) | 1 084 (85) | 2 105 (75) | |
| | BCG vaccination | No evidence of BCG | | | | |
| | | vaccination | 45 (8) | 89 (7) | 152 (5) | |
| | | Unknown | 34 (6) | 97 (8) | 561 (20) | |
| | | HIV-positive | 111 (21) | 396 (31) | 464 (16) | |
| | HIV status | HIV-negative | 425 (79) | 841 (66) | 2 254 (80) | |
| | | Unknown | 5 (1) | 33 (3) | 100 (4) | |
| | | No couah | 75 (14) | 205 (16) | 823 (29) | |
| | | Cough 0-13 days | 148 (27) | 279 (22) | 598 (21) | |
| | | Cough 14-20 days | 90 (17) | 140 (11) | 321 (11) | |
| | Cough duration | Cough 21-27 days | 52 (10) | 96 (8) | 224 (8) | |
| | | Cough >27 days | 125 (23) | 260 (20) | 512 (18) | |
| | | Unknown | 51 (0) | 200 (20) | 340 (12) | |
| | | Courdh >2 weeks present | 295 (55) | 697 (55) | 1 247 (44) | |
| | Courde > 2 weeks | $Cough \ge 2$ weeks not present | 238 (11) | 562 (11) | 1531 (54) | |
| | Cough 2 weeks | Unknown | 8 (1) | 11 (1) | 1001(04) | |
| | | No fovor | 0(1) | 252 (28) | 40 (1) | |
| | | Fover 0.12 days | 140 (27) | 291 (22) | 712 (25) | |
| | | Fever 0-13 days | 67 (12) | 122 (10) | 262 (0) | |
| | Fever duration | Fever 14-20 days | 20 (4) | 122 (10) | 202 (9) | |
| | | Fever 21-27 days | 20 (4) | 40 (3) | 00 (J) 194 (Z) | |
| | | Fever >27 udys | 77 (14) | 119 (9) | 104 (1) | |
| | | | 90 (10) | 300 (20) | 410 (10) | |
| | Fover >1 wook | Fever 21 week present | 209 (39) | 300 (31) | 119 (28) | |
| | rever 21 week | Fever 21 week not present | 242 (43) | | | |
| | | | 90 (17) | 232 (18) | 263 (9) | |
| | L ath annua | Lethargy | 268 (50) | 479 (38) | 838 (30) | |
| | Lethargy | No lethargy | 226 (42) | 565 (44) | 1 204 (43) | |
| | | Unknown | 47 (9) | 226 (18) | 776 (28) | |
| | | Weight loss | 358 (66) | 763 (60) | 1 631 (58) | |
| | weight loss | INO Weight loss | 172 (32) | 492 (39) | 1 155 (41) | |
| | | Unknown | 11 (2) | 15 (1) | 32 (1) | |
| | | | | | | |
| | | exposure in previous 12 | 257 (40) | 404 (20) | 407 (40) | |
| | Documented tuberculosis | Monuns | 257 (48) | 491 (39) | 497 (18) | |
| | exposure | No documented tuberculosis | | | | |
| | - | exposure in previous 12 | 294 (52) | 775 (64) | 224E(22) | |
| | | Hindhuns | 204 (52) | 115 (61) | 2313 (oz) 6 (0) | |
| | | Unknown Night gwasta | 0(0) | 4 (0) | 6 (U) 569 (20) | |
| | Night owned | No pight sweets | 200 (30) | 422 (33) | 1 945 (CE) | |
| | Night Sweats | | 107 (35) | 077 (45) | | |
| | | | 148 (27) | 2/1 (21) | 405 (14) | |
| | | Haemoptysis | ∠ (U) | 13 (1) | 12 (U) | |
| | Haemoptysis | INO NAEMOPTYSIS | 88 (16) | 410 (32) | 851 (30) | |
| | | Unknown | 451 (83) | 847 (67) | 1 955 (69) | |
| | Objective fever (≥38 | Objective fever | /1 (13) | 101 (8) | 156 (6) | |
| | degrees Celsius) | No objective fever | 228 (42) | 738 (58) | 1 476 (52) | |
| | | Unknown | 242 (45) | 431 (34) | 1 186 (42) | |
| | Tachycardia | Tachycardia | 80 (15) | 150 (12) | 175 (6) | |

| | No tachycardia | 179 (33) | 611 (48) | 1 187 (42) |
|---|--------------------------------|----------|-----------|------------|
| Unknown | | 282 (52) | 509 (40) | 1 456 (52) |
| | Tachypnoea | 128 (24) | 264 (21) | 320 (11) |
| Tachypnoea | No tachypnoea | 276 (51) | 742 (58) | 1 494 (53) |
| | Unknown | 137 (25) | 264 (21) | 1 004 (36) |
| | Peripheral lymphadenopathy | 134 (25) | 242 (19) | 280 (10) |
| Peripheral | No peripheral | - (-/ | (- / | |
| lymphadenopathy | lymphadenopathy | 295 (55) | 759 (60) | 1 444 (51) |
| ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | Unknown | 112 (21) | 269 (21) | 1 094 (39) |
| | Xpert positive for Mtb | 247 (46) | 0 (0) | 0 (0) |
| First Xpert MTB/RIF | Xpert negative for Mtb | 273 (50) | 1148 (90) | 2 306 (82) |
| | Unknown/not performed | 21 (4) | 122 (10) | 512 (18) |
| | CXR consistent with | - · (·) | () | 0.2(10) |
| | tuberculosis | 344 (64) | 644 (51) | 653 (23) |
| Overall CXR read | CXR not consistent with | 0(0.) | 0.1.(0.) | 000 (20) |
| | tuberculosis | 101 (19) | 474 (37) | 1 744 (62) |
| | Unknown/not assessed | 96 (18) | 152 (12) | 421 (15) |
| | Opacities present on CXR | 237 (44) | 487 (38) | 594 (21) |
| | Opacities not present on | | | |
| Opacities on CXR | CXR | 154 (28) | 459 (36) | 1 042 (37) |
| | Unknown/not assessed | 150 (28) | 324 (26) | 1 182 (42) |
| | Cavities present on CXR | 32 (6) | 25 (2) | 20 (1) |
| Cavities on CXR | Cavities not present on CXR | 348 (64) | 793 (62) | 973 (35) |
| | Unknown/not assessed | 161 (30) | 452 (36) | 1 825 (65) |
| | Miliary infiltrate present on | | .02 (00) | |
| | CXR | 33 (6) | 19 (1) | 7 (0) |
| Miliary infiltrate on CXR | Miliary infiltrate not present | | - () | |
| 2 | on CXR | 358 (66) | 927 (73) | 1 614 (57) |
| | Unknown/not assessed | 150 (28) | 324 (26) | 1 197 (42) |
| | Intrathoracic | | - (-/ | |
| | lymphadenopathy present | | | |
| | on CXR | 154 (28) | 248 (20) | 104 (4) |
| Intratnoracic | Intrathoracic | | | |
| lymphadenopathy on CXR | lymphadenopathy not | | | |
| | present on CXR | 237 (44) | 684 (54) | 1 485 (53) |
| | Unknown/not assessed | 150 (28) | 338 (27) | 1 229 (44) |
| | Pleural effusion present on | | | |
| | CXR | 56 (10) | 63 (5) | 49 (2) |
| Pleural effusion on CXR | Pleural effusion not present | | | |
| | on CXR | 335 (62) | 883 (70) | 1 570 (56) |
| | Unknown/not assessed | 150 (28) | 324 (26) | 1 199 (43) |
| | TST positive | 298 (55) | 464 (37) | 262 (9) |
| Tuberculin skin test | TST negative | 174 (32) | 674 (53) | 1 972 (70) |
| | Unknown/not performed | 69 (13) | 132 (10) | 584 (21) |

567 Table 3. Estimates from logistic regression prediction model to classify pulmonary tuberculosis

using variables from initial evaluation. Parameter estimate with 95% confidence intervals, odds ratio estimate with 95% confidence interval, and p-values for each parameter included in the logistic regression

570 prediction model. The estimate provided for each predictor is computed against a reference that reflects 571 the absence of that feature. The model parameter estimates account for potential clustering at the study-

572 level as well as uncertainty introduced by missing data. *P-value calculated using Rubin's rules for

573 multiple imputed data. OR – odds ratio, CI – confidence interval, CXR – chest x-ray.

| Predictors | Coefficient | Coefficient 95% CI | OR | OR 95% CI | P-value* |
|---|-------------|-----------------------|------|------------|----------|
| Intercept | -1.92 | -2.58, -1.25 | | | |
| Cough duration ≥2 weeks (Absence is no cough or cough <2 weeks) | 0.17 | -0.09, 0.43 | 1.19 | 0.91, 1.54 | 0.86 |
| Fever duration ≥2 weeks (Absence is no fever or fever <2 weeks) | 0.45 | 0.16, 0.74 | 1.57 | 1.18, 2.09 | 0.25 |
| Lethargy | 0.25 | 0.02, 0.48 | 1.28 | 1.02, 1.62 | 0.66 |
| Weight loss | 0.22 | -0.03, 0.48 | 1.25 | 0.97, 1.62 | 0.75 |
| History of documented tuberculosis exposure | 1.43 | 0.87, 2.00 | 4.20 | 2.39, 7.38 | <0.001 |
| Haemoptysis | 0.34 | -0.37, 1.05 | 1.40 | 0.69, 2.86 | 0.78 |
| Night sweats | 0.2 | 0.02, 0.38 | 1.22 | 1.02, 1.47 | 0.71 |
| Peripheral lymphadenopathy | 0.35 | 0.13, 0.57 | 1.42 | 1.14, 1.77 | 0.35 |
| Temperature ≥38 Celsius | 0.00 | -0.25, 0.26 | 1.00 | 0.78, 1.30 | >0.999 |
| Tachycardia | 0.15 | -0.13, 0.42 | 1.16 | 0.88, 1.53 | 0.90 |
| Tachypnoea | -0.05 | -0.27, 0.16 | 0.95 | 0.77, 1.18 | 0.98 |
| Cavities on CXR | 0.47 | -0.11, 1.05 | 1.60 | 0.90, 2.85 | 0.53 |
| Intrathoracic lymphadenopathy on CXR | 1.46 | 1.00, 1.92 | 4.32 | 2.73, 6.85 | <0.001 |
| Opacities on CXR | 0.43 | 0.02, 0.84 | 1.54 | 1.02, 2.32 | 0.45 |
| Miliary infiltrate on CXR | 1.27 | 0.57, 1.97 | 3.56 | 1.76, 7.19 | <0.001 |
| Pleural effusion on CXR | 0.64 | 0.2, 1.09 | 1.90 | 1.22, 2.96 | 0.13 |

575 FIGURES

576 Figure 1. Performance of existing treatment-decision algorithms at classifying tuberculosis.

Retrospective estimates of the pooled (A) sensitivity and (B) specificity of eight algorithms to guide
decisions to treat children with presumptive pulmonary tuberculosis, had they been used to evaluate the
children for whom we have IPD records. The reference classification of pulmonary tuberculosis included
bacteriologically-confirmed pulmonary tuberculosis as well as unconfirmed pulmonary tuberculosis.
Modifications were made to the algorithms to maximise the use of the available IPD. IPD – individual
participant data. HIV – human immunodeficiency virus. BD – Bangladesh. BR – Brazil, KE – Kenva, MM –

583 Myanmar, Multi – (PAANTHER) Multi-country study (includes Burkina Faso, Cameroon, Vietnam, and

- 584 Cambodia), MZ Mozambique, PK Pakistan, UG Uganda, VN Vietnam, ZA South Africa, MoH –
- 585 (Brazil) Ministry of Health, NTLP (Uganda) National TB and Leprosy Program. *Performance estimates
- 586 of the Marcy et al. Algorithm were derived from only HIV-positive children in the IPD that excludes data
- 587 form the Marcy/2016/Multi cohort (from which the algorithm was developed), **Performance estimates of 588 the Gunasekera et al. Algorithm were derived from only HIV-negative children in the IPD that excludes
- 589 data from the Walter/2017/ZA population (from which the algorithm was developed).



591 Figure 2. Forest plot depicting performance of scaled scores from prediction model to classify 592 tuberculosis with 85% sensitivity. Study-level and pooled estimates of the (A) sensitivity and (B) 593 specificity of classifying tuberculosis (composite reference standard: bacteriologically-confirmed 594 pulmonary tuberculosis and unconfirmed pulmonary tuberculosis) of the scores derived from the prediction model developed from the IPD to classify TB with 85% sensitivity. IPD - individual participant 595 596 data, BD – Bangladesh, BR – Brazil, KE – Kenya, MM – Myanmar, Multi – Multi-country study (includes 597 Burkina Faso, Cameroon, Vietnam, and Cambodia), MZ – Mozambique, PK – Pakistan, UG – Uganda, 598 VN – Vietnam, ZA – South Africa.



599

600

602 Figure 3. Treatment-decision algorithm including chest x-ray features derived from the prediction 603 model. Tuberculosis treatment-decision algorithm for use among children <10 years with symptoms 604 suggestive of pulmonary tuberculosis, reproduced from the operational handbook accompanying the WHO consolidated guidelines on the management of tuberculosis in children and adolescents.^{12,13} 605 606 Selection steps prior to entering scoring system reflect recommendations from the WHO expert panel to 607 enrich the probability of tuberculosis among the population of children proceeding through the algorithm 608 to the model such that the probability would more closely reflect the preselected population producing the 609 data from which the prediction model was built while balancing the consequences of untreated 610 tuberculosis among high-risk children. Scores associated with features from clinical history and physical 611 exam and chest X-ray translate to risk of tuberculosis and are scaled from the prediction model 612 developed from the IPD. Guidance on the practical use of this algorithm is outlined in the WHO 613 operational handbook. WHO - World Health Organization, TB - tuberculosis, IPD - individual participant 614 data, HIV - human immunodeficiency virus, mWRD - molecular WHO-recommended rapid diagnostic test. CLHIV - children living with HIV, LF-LAM - lateral flow urine lipoarabinomannan assay, CXR - chest 615 616 X-rav.



| 618 | AUTHOR AFFILIATIONS |
|------------|--|
| 619 | Name: Kenneth S. Gunasekera |
| 620 | Degree: PhD |
| 621 | Affiliation(s): |
| 622 | 1. Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New |
| 623 | Haven, USA |
| 624 | |
| 625 | Name: Olivier Marcy |
| 626 | Degree: PhD |
| 627 | Affiliation(s): |
| 628 | 1 University of Bordeaux Inserm UMR1219 Institut de Recherche nour le Développement |
| 620 | (IRD) EMR 271 Bordeaux France |
| 630 | (IICD) EMIC 271, Doldeaux Flance |
| 631 | Name: Johanna Muñoz |
| 622 | Degree: M Se |
| 03Z | Affiliation (a): |
| 033 | Anniauon(s). |
| 634 005 | I. Julius Center for Health Sciences and Primary Care, University Medical Center Otrecht, |
| 635 | Utrecht University, Utrecht, The Netherlands |
| 636 | |
| 637 | Name: Elisa Lopez-Vareia |
| 638 | Degree: MD, PhD |
| 639 | Affiliation(s): |
| 640 | 1. Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - Universitat de Barcelona, |
| 641 | Barcelona, Spain |
| 642 | |
| 643 | Name: Moorine Penninah Sekadde |
| 644 | Degree: MD |
| 645 | Affiliation(s): |
| 646 | National Tuberculosis and Leprosy Program, Kampala, Uganda |
| 647 | |
| 648 | Name: Molly F. Franke |
| 649 | Degree: ScD |
| 650 | Affiliation(s): |
| 651 | 1. Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA |
| 652 | |
| 653 | Name: Maryline Bonnet |
| 654 | Degree: MD, PhD |
| 655 | Affiliation(s): |
| 656 | 1. University of Montpellier, Inserm, Institut de Recherche pour le Développement, TransVIHMI, |
| 657 | Montpellier, France |
| 658 | 2. Epicentre, Mbarara, Uganda |
| 659 | |
| 660 | Name: Shakil Ahmed |
| 661 | Degree: FCPS |
| 662 | Affiliation(s): |
| 663 | 1. Department of Paediatrics, Dhaka Medical College Hospital, Dhaka, Bangladesh |
| 664 | |
| 665 | Name: Farhana Amanullah |
| 666 | Degree: FAAP |
| 667 | Affiliation(s): |
| 668 | 1. Indus Hospital & Health Network, Karachi, Pakistan |

669 2. The Aga Khan University Hospital, Karachi, Pakistan 670 671 Name: Aliya Anwar 672 Degree: FCPS 673 Affiliation(s): 674 1. Indus Hospital & Health Network, Karachi, Pakistan 675 676 Name: Orvalho Augusto 677 Degree: MD 678 Affiliation(s): 679 1. Centro de Investigação em Saúde de Manhica, Maputo, Mozambigue 680 681 Name: Rafaela Baroni Aurilio 682 Degree: MD, PhD 683 Affiliation(s): 684 1. Instituto de Puericultura e Pediatria Martagao Gesteira. Universidade Federal do Rio de 685 Janeiro, Rio de Janeiro, Brazil 686 687 Name: Sayera Banu 688 Degree: PhD 689 Affiliation(s): 690 1. Programme on Emerging Infections, Infectious Disease Division, icddr,b, Dhaka, Bangladesh 691 692 Name: Iraj Batool 693 Degree: --694 Affiliation(s): 695 1. Indus Hospital & Health Network, Karachi, Pakistan 696 697 Name: Annemieke Brands 698 Degree: MPH 699 Affiliation(s): 700 1. Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland 701 702 Name: Kevin P. Cain Degree: MD 703 704 Affiliation(s): 705 1. US Centers for Disease Control and Prevention, Atlanta, USA 706 707 Name: Lucía Carratalá-Castro 708 Degree: MD 709 Affiliation(s): 710 1. Manhica Health Research Centre, Maputo, Mozambique 711 2. Barcelona Institute for Global Health, Barcelona, Spain 712 713 Name: Maxine Caws 714 Degree: PhD 715 Affiliation(s): 1. Liverpool School of Tropical Medicine, Liverpool, UK 716 717

718 Name: Eleanor S. Click

719 Degree: MD 720 Affiliation(s): 721 1. US Centers for Disease Control and Prevention, Atlanta, USA 722 723 Name: Lisa M. Cranmer 724 Degree: MD 725 Affiliation(s): 726 1. Emory School of Medicine, Atlanta, USA 727 2. Emory Rollins School of Public Health, Atlanta, USA 728 3. Children's Healthcare of Atlanta, Atlanta, USA 729 730 Name: Alberto L. García-Basteiro 731 Degree: PhD 732 Affiliation(s): 733 1. Centro de Investigação em Saúde de Manhica, CISM, e; Maputo, Mozambique 734 2. ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; 735 3. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), 736 Barcelona, Spain 737 738 Name: Anneke C. Hesseling 739 Degree: MD, PhD 740 Affiliation(s): 741 1. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine 742 and Health Sciences, Stellenbosch University, Tygerberg, South Africa 743 744 Name: Julie Huynh 745 Degree: MBBS 746 Affiliation(s): 747 1. Oxford University Clinical Research Unit, Centre for Tropical Diseases, Ho Chi Minh City, 748 Vietnam 749 2. Nuffield Department of Medicine, Oxford University, UK 750 751 Name: Senjuti Kabir 752 Degree: MPH 753 Affiliation(s): 754 1. Programme on Emerging Infections, Infectious Disease Division, icddr,b, Dhaka, Bangladesh 755 756 Name: Leonid Lecca 757 Degree: MD 758 Affiliation(s): 759 1. Socios En Salud Surcursal Perú, Lima, Perú 2. Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA 760 761 762 Name: Anna Mandalakas 763 Degree: PhD 764 Affiliation(s): 765 1. Global TB Program, Baylor College of Medicine and Texas Children's Hospital, Houston, USA 766 2. Clinical Infectious Disease Group, German Center for Infectious Research (DZIF), Clinical TB 767 Unit, Research Center Borstel, Borstel, Germany 768 769 Name: Farai Mavhunga

- 770 Degree: MPH 771 Affiliation(s): 1. Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland 772 773 774 Name: Ave Ave Mvint 775 Degree: Dr.Med.Sc (Paediatrics) 776 Affiliation(s): 777 1. Department of Paediatrics, University of Medicine, Mandalay, Myanmar 778 779 Name: Kyaw Myo 780 Degree: Dr.Med.Sc (Paediatrics) 781 Affiliation(s): 782 1. Department of Paediatrics, University of Medicine, Magway, Myanmar 783 784 Name: Dorah Nampijia 785 Degree: MMed (Pediatrics) 786 Affiliation(s): 787 1. Mbarara University of Science and Technology, Mbarara, Uganda 788 789 Name: Mark P. Nicol 790 Dearee: PhD 791 Affiliation(s): 792 1. Division of Infection and Immunity, Department of Biomedical Sciences, University of Western 793 Australia, Perth, Australia 794 795 Name: Patrick Orikiriza 796 Degree: PhD 797 Affiliation(s): 798 1. Epicentre, Mbarara, Uganda 799 2. Department of Microbiology, Division of Basic Medical Sciences, School of Medicine, 800 University of Global Health Equity, Kigali, Rwanda 801 802 Name: Megan Palmer 803 Degree: MMed 804 Affiliation(s): 805 1. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine 806 and Health Sciences, Stellenbosch University, Tygerberg, South Africa 807 808 Name: Clemax Couto Sant'Anna 809 Degree: PhD, MD 810 Affiliation(s): 811 1. Faculty of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil 812 813 Name: Sara Ahmed Siddigui 814 Degree: MBA 815 Affiliation(s): 816 1. Indus Hospital & Health Network, Karachi, Pakistan 817 Name: Jonathan P. Smith 818
- 819 Degree: PhD
- 820 Affiliation(s):

- 1. Department of Health Policy and Management, Yale School of Public Health, New Haven,
- 822 USA
- 823 2. US Centers for Disease Control and Prevention, Atlanta, USA
- 824
- 825 Name: Rinn Song
- 826 Degree: MD
- 827 Affiliation(s):
- 828 1. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
- 829 2. Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts;
- 830 3. Department of Pediatrics, Harvard Medical School, Boston, USA
- 831
- 832 Name: Nguyen Thuy Thuong Thuong
- 833 Degree: PhD
- 834 Affiliation(s):
- 1. Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
- 836 2. Nuffield Department of Medicine, Centre for TropicalMedicine and Global Health, University
- 837 of Oxford, Oxford, UK
- 838
- 839 Name: Vibol Ung
- 840 Degree: MD
- 841 Affiliation(s):
- 842 1. University of Health Sciences, Phnom Penh, Cambodia
- 843 2. National Pediatric Hospital, Phnom Penh, Cambodia
- 844
- 845 Name: Marieke van der Zalm
- 846 Degree: PhD
- 847 Affiliation(s):
- 848 1. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine
- and Health Sciences, Stellenbosch University, Tygerberg, South Africa
- 850
- 851 Name: Sabine Verkuijl
- 852 Degree: MD, MMed
- 853 Affiliation(s):
- 1. Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland
- 855
- 856 Name: Kerri Viney
- 857 Degree: PhD
- 858 Affiliation(s):
- 1. Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland
- 860 2. School of Public Health, University of Sydney, Sydney, Australia
- 861
- 862 Name: Elisabetta G. Walters
- 863 Degree: PhD
- 864 Affiliation(s):
- 865 1. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine
 866 and Health Sciences, Stellenbosch University, Tygerberg, South Africa
- 867 2. Directorate of Integrated Laboratory Medicine, Institute of Human Genetics, Newcastle upon
- 868 Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
- 869
- 870 Name: Joshua L. Warren
- 871 Degree: PhD

- 872 Affiliation(s):
- 1. Department of Biostatistics, Yale School of Public Health, New Haven, USA
- 874
- 875 Name: Heather J. Zar
- 876 Degree: PhD
- 877 Affiliation(s):
- 878 1. Department of Paediatrics & Child Health, Red Cross Children's Hospital, Cape Town, South879 Africa
- 880 2. SA-MRC Unit on Child & Adolescent Health, University of Cape Town, South Africa
- 881
- 882 Name: Ben J. Marais
- 883 Degree: PhD
- 884 Affiliation(s):
- 1. The Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health,
- 886 University of Sydney, Sydney, Australia
- 887
- 888 Name: Stephen M. Graham
- 889 Degree: PhD
- 890 Affiliation(s):
- 1. University of Melbourne Department of Paediatrics and Murdoch Children's Research
- 892 Institute, Royal Children's Hospital, Melbourne, Australia
- 893 2. Burnet Institute, Melbourne, Australia
- 894
- 895 Name: Thomas P. A. Debray
- 896 Degree: PhD
- 897 Affiliation(s):
- 1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht,
- 899 Utrecht University, Utrecht, The Netherlands
- 900
- 901 Name: Ted Cohen
- 902 Degree: DPH
- 903 Affiliation(s):
- 1. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New
- 905 Haven, USA
- 906
- 907 Name: James A. Seddon
- 908 Degree: PhD
- 909 Affiliation(s):
- 910 1. Desmond Tutu Tuberculosis Centre, Department of Paediatrics and Child Health, Faculty of
- 911 Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
- 912 2. Department of Infectious Diseases, Imperial College London, London, UK